Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cambrex and The Dow Chemical Company have collaborated to manufacture drug-solubility solution, Dow Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS), to enhance drug solubility.
Subscribe to our email newsletter
The final step in the solubilization partnership between the companies is expected to aid Dow to commercially supply solubility enabling excipients.
Dow senior R&D director Bob Maughon said, "The AFFINISOL™ product platform has excellent manufacturing flexibility to match the diverse excipients needs of our customers’ pipelines."
The product is scheduled to be commercially available by the end of 2013.
Construction commenced on the new operational facility at Cambrex Karlskoga.
Cambrex sales and business development VP Eric Neuffer said, "This agreement between Dow and Cambrex further validates Cambrex’s commitment to finding solutions that offer our clients quality products and services to meet a market need."